Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.63 |
| ▸ | LTA4H | P09960 | 3/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135900 | 0.97 | ESR1 (0.62) | ESR1ESR2LTA4HSSTR2F2 | |
| SCHEMBL6135990 | 0.97 | ESR1 (0.64) | ESR1ESR2LTA4HSSTR2F2 | |
| SCHEMBL6135934 | 0.94 | ESR1 (0.63) | ESR1ESR2LTA4HSSTR2F2 | |
| SCHEMBL6136215 | 0.94 | ESR1 (0.65) | ESR1ESR2LTA4HSSTR2F2 | |
| SCHEMBL3714380 | 0.92 | ESR1 (0.64) | ESR1ESR2LTA4HSSTR2F2 | |
| Hydrochloric Acid SCHEMBL5256714 | 0.91 | ESR1 (0.66) | ESR1ESR2LTA4HSSTR2F2 | |
| SCHEMBL6136203 | 0.89 | ESR1 (0.59) | ESR1ESR2LTA4H | |
| SCHEMBL6136055 | 0.87 | ESR1 (0.58) | ESR1ESR2F2 | |
| SCHEMBL6135908 | 0.86 | ESR1 (0.59) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL6004702 | 0.86 | ESR1 (0.59) | ESR1ESR2LTA4HSSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | claimed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | claimed |
| WO-1999007377-A1 | 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | claimed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | disclosed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | disclosed |